These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16118109)

  • 1. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T; Furuland H; Wikström B
    Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M; Premru V
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing anaemia management with subcutaneous administration of epoetin.
    Besarab A
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
    Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
    Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
    Kleophas W
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration.
    Decaudin B; Lemaitre V; Gautier S; Urbina MA
    J Clin Pharm Ther; 2004 Aug; 29(4):325-9. PubMed ID: 15271099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM; Collins DM; Penner SB
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
    Galliford JW; Malasana R; Farrington K
    Nephrol Dial Transplant; 2005 Sep; 20(9):1956-62. PubMed ID: 15930017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.